Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

(2021) Alexis Moscoso et al.   JAMA Neurology

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

(2020) Nicolas R. Barthélemy et al.   Alzheimers Research & Therapy

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease

(2020) Stephanie A. Schultz et al.   NEUROBIOLOGY OF DISEASE

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations

(2020) Federica Perrone et al.   Alzheimers Research & Therapy

Comparison of cerebrospinal fluid phosphorylated tau 181 and 217 for cognitive progression

(2020) Michelle M. Mielke et al.   Alzheimers & Dementia

CSF phosphorylated tau‐217 is increased in Alzheimer’s and Creutzfeldt‐Jakob diseases and correlates with amyloid pathology

(2020) Andreja Emeršič et al.   Alzheimers & Dementia

Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls

(2020) Hlin Kvartsberg et al.   Alzheimers & Dementia

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

(2020) Thomas K. Karikari et al.   Alzheimers & Dementia

Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

(2020) Jasmeer P. Chhatwal et al.   Nature Communications

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

(2019) Nicholas J. Ashton et al.   Acta Neuropathologica Communications

Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes

(2019) Matthew P. Pase et al.   JAMA Neurology

Blood-based molecular biomarkers for Alzheimer’s disease

(2019) Henrik Zetterberg et al.   Molecular Brain

Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer’s disease

(2019) Philippe Bourassa et al.   ACTA NEUROPATHOLOGICA

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Disease signatures: Biomarkers/indicators of neurodegeneration

(2019) Henrik Zetterberg et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

A Unifying Hypothesis for Alzheimer’s Disease: From Plaques to Neurodegeneration

(2019) Frances A. Edwards   TRENDS IN NEUROSCIENCES

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization

(2019) Lieke Jäkel et al.   Acta Neuropathologica Communications

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease

(2019) Pratishtha Chatterjee et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

(2019) Nicholas J. Ashton et al.   Alzheimers Research & Therapy

Intracellular sensing of viral genomes and viral evasion

(2019) Hyun-Cheol Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease

(2018) Henrik Zetterberg et al.   JOURNAL OF ALZHEIMERS DISEASE

A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication

(2018) Liu Shi et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Tauomics and Kinetics in Human Neurons and Biological Fluids

(2018) Henrik Zetterberg   NEURON

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Highly Sensitive and Multiplexed Protein Measurements

(2018) Limor Cohen et al.   CHEMICAL REVIEWS

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

(2018) Armand Perret-Liaudet et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels

(2018) Sylvie Slaets et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study

(2018) Diego Albani et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

(2018) Piotr Lewczuk et al.   Alzheimers Research & Therapy

Current state of Alzheimer’s fluid biomarkers

(2018) José Luis Molinuevo et al.   ACTA NEUROPATHOLOGICA

Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease

(2018) Zhicheng Chen et al.   Alzheimers & Dementia

Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer’s Disease: A Case Report

(2018) Willem S. Eikelboom et al.   JOURNAL OF ALZHEIMERS DISEASE

Blood-based biomarkers for Alzheimer’s disease—An update

(2018) Henrik Zetterberg   JOURNAL OF NEUROSCIENCE METHODS

Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease

(2018) Yung-Shuan Lin et al.   Scientific Reports

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

(2018) Raquel Sánchez-Valle et al.   Alzheimers Research & Therapy

Microglia in Alzheimer’s disease

(2017) David V. Hansen et al.   JOURNAL OF CELL BIOLOGY

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

(2017) Harutsugu Tatebe et al.   Molecular Neurodegeneration

Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease

(2017) Simone Lista et al.   NEUROCHEMISTRY INTERNATIONAL

Serum neurofilament light in familial Alzheimer disease

(2017) Philip S.J. Weston et al.   NEUROLOGY

Blood-based NfL

(2017) Oskar Hansson et al.   NEUROLOGY

Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42

(2017) Camilla Lauridsen et al.   Frontiers in Aging Neuroscience

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

(2017) Shorena Janelidze et al.   JAMA Neurology

Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging

(2017) Michelle M. Mielke et al.   JAMA Neurology

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort

(2016) Jeffrey L. Dage et al.   Alzheimers & Dementia

Molecular genetics of early-onset Alzheimer's disease revisited

(2016) Rita Cacace et al.   Alzheimers & Dementia

Recent Advances in Electrochemiluminescence Analysis

(2016) Lingling Li et al.   ANALYTICAL CHEMISTRY

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

(2016) Niklas Mattsson et al.   EMBO Molecular Medicine

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

(2016) Marc Suárez‐Calvet et al.   EMBO Molecular Medicine

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

(2016) Hugo Marcel Johan Vanderstichele et al.   JOURNAL OF ALZHEIMERS DISEASE

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer’s Disease and Dementia with Lewy Bodies

(2016) Olivier Bousiges et al.   JOURNAL OF ALZHEIMERS DISEASE

Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity

(2016) Nicolas R Barthélemy et al.   JOURNAL OF PROTEOME RESEARCH

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

(2016) Amanda Heslegrave et al.   Molecular Neurodegeneration

A polarizing question: do M1 and M2 microglia exist?

(2016) Richard M Ransohoff   NATURE NEUROSCIENCE

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Plasma tau in Alzheimer disease

(2016) Niklas Mattsson et al.   NEUROLOGY

How neuroinflammation contributes to neurodegeneration

(2016) R. M. Ransohoff   SCIENCE

Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study

(2016) Camilla Lauridsen et al.   Frontiers in Aging Neuroscience

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

Advances in mass spectrometry-based clinical biomarker discovery

(2016) Christopher A. Crutchfield et al.   Clinical Proteomics

Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients

(2016) Shashank Shekhar et al.   PLoS One

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Explorative and targeted neuroproteomics in Alzheimer's disease

(2015) Ann Brinkmalm et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding

(2015) Kaj Blennow et al.   NATURE MEDICINE

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies

(2015) Malin Wennström et al.   PLoS One

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls

(2015) Hlin Kvartsberg et al.   Alzheimers Research & Therapy

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

(2014) Frank Jessen et al.   Alzheimers & Dementia

The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease

(2014) Josef Pannee et al.   NEUROSCIENCE LETTERS

CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?

(2014) William T. Hu et al.   Annals of Clinical and Translational Neurology

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

(2013) Alan Rembach et al.   Alzheimers & Dementia

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

(2013) Harald Hampel et al.   BIOCHEMICAL PHARMACOLOGY

The Diagnostic Value of CSF Amyloid-β43 in Differentiation of Dementia Syndromes

(2013) Kim Bruggink et al.   Current Alzheimer Research

Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease

(2013) Ming-Jang Chiu et al.   HUMAN BRAIN MAPPING

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Idiopathic normal-pressure hydrocephalus: Pathophysiology and diagnosis by CSF biomarkers

(2013) A. Jeppsson et al.   NEUROLOGY

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

(2013) Jere E. Meredith Jr. et al.   PLoS One

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

Plasma tau levels in Alzheimer's disease

(2013) Henrik Zetterberg et al.   Alzheimers Research & Therapy

Development and Advanced Validation of an Optimized Method for the Quantitation of Aβ42 in Human Cerebrospinal Fluid

(2012) Valerie C. Cullen et al.   AAPS Journal

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

(2012) Eric M Reiman et al.   LANCET NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study

(2012) Jeffrey Randall et al.   RESUSCITATION

Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology

(2011) Anne M. Fagan   ARCHIVES OF NEUROLOGY

Neurodegenerative disease and adult neurogenesis

(2011) Beate Winner et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Potent amyloidogenicity and pathogenicity of Aβ43

(2011) Takashi Saito et al.   NATURE NEUROSCIENCE

Post-translational modifications of tau protein: Implications for Alzheimer's disease

(2011) Ludovic Martin et al.   NEUROCHEMISTRY INTERNATIONAL

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

(2011) N. S. M. Schoonenboom et al.   NEUROLOGY

Tau in Alzheimer Disease and Related Tauopathies

(2010) K. Iqbal et al.   Current Alzheimer Research

The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Aβ in different brain regions

(2010) Lina Keller et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

(2010) David M Rissin et al.   NATURE BIOTECHNOLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

(2009) Volker Welge et al.   JOURNAL OF NEURAL TRANSMISSION

Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains

(2009) Hedvig Welander et al.   JOURNAL OF NEUROCHEMISTRY

Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease

(2008) C.-X. Gong et al.   CURRENT MEDICINAL CHEMISTRY

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

(2008) Oskar Hansson et al.   NEUROBIOLOGY OF AGING